ClearPoint Neuro Inc. (CLPT) Stock

About ClearPoint Neuro Inc.

ClearPoint Neuro Inc. is led by CEO Joseph Michael Burnett, employs 115 people, headquartered in US, publicly traded since 2012.

ClearPoint Neuro Inc. (CLPT) stock trades at $9.14 with a market capitalization of $278.81M. The stock is valued at a negative price-to-earnings (P/E) ratio of -12.57, reflecting a net loss over the last twelve months, price-to-book of 41.09, price-to-sales of 10.52. Over the past 52 weeks the stock has ranged between $8.27 and $30.10, and currently trades 69.6% below its 52-week high.

On profitability, ClearPoint Neuro Inc. generates a return on equity (ROE) of -188.09% (negative, reflecting a net loss), return on capital employed of -40.62%, an operating margin of -64.86%, a net profit margin of -81.76%.

ClearPoint Neuro Inc. by the numbers, 2016–2025

Between 2016 and 2025 ClearPoint Neuro Inc. reported revenue of $6.0M rising to $37.0M, a change of +516.7% across 10 years. Compounded, revenue has grown 23.3% a year over five years, 20.8% over three, 19.4% over the last twelve months. Net profit fell to $-26.0M.

Operating margin went from -130.3% in 2016 to -65.4% in 2025, a gain of 64.9 percentage points. The most recent net margin is -81.76%. On a trailing twelve-month basis to Jun '26, revenue is $42.0M and net profit $-35.0M.

Borrowings rose from $4.0M to $58.0M, cash from operations was $-24.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -69.1% over five years, and was -92.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

ClearPoint Neuro Inc. (CLPT) — frequently asked questions